Funded in part by Quest Diagnostics
Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial
Wetmore JB, Kimber C, Mahnken JD, Stubbs JR
The British journal of nutrition · 25 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Quest Diagnostics
- Government
- National Institute of Diabetes and Digestive and Kidney Diseases
- Government
- National Center for Advancing Translational Sciences
- Government
- NIDDK NIH HHS
- Government
- NCATS NIH HHS
- Grants
- National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK085378); National Center for Advancing Translational Sciences (UL1TR000001)
Based on 5 listed funder(s).
Publication
- Published
- 2016-12-28 · Br J Nutr · vol. 116 · issue 12 · pp. 2074–2081
- Publisher
- Cambridge University Press
- Cited
- 35 citations · more than 92% of similar papers · 3.2× the field average
- Impact
- Top 10% most cited in its field
- References
- 31 works
- Access
- Free to read
- Research areas
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Pancreatitis Pathology and Treatment
- Keywords
- Ergocalciferol, Cholecalciferol, Vitamin D and neurology, Medicine, Internal medicine, vitamin D deficiency, Endocrinology, Kidney disease, Gastroenterology, Parathyroid hormone, Population, Calcium
- MeSH
- humans, vitamin d deficiency, cholecalciferol, calcifediol, calcitriol, ergocalciferols, 25-hydroxyvitamin d 2, parathyroid hormone, cohort studies, follow-up studies, double-blind method, reproducibility of results, dietary supplements, adult, aged, middle aged, academic medical centers, outpatient clinics, hospital, kansas, female, male, renal insufficiency, chronic
4 authors
From US
- James B. WetmoreHennepin County Medical Center
- Cassandra KimberUniversity of Kansas Medical Center
- Jonathan D. MahnkenUniversity of Kansas Medical Center
- Jason R. Stubbs · correspondingUniversity of Kansas Medical Center
Abstract
Patients with chronic kidney disease (CKD) demonstrate complex mineral metabolism derangements and a high prevalence of vitamin D deficiency. However, the optimal method of 25-hydroxyvitamin D (25(OH)D) repletion is unknown, and trials analysing the comparative efficacy of cholecalciferol and ergocalciferol in this population are lacking. We conducted a randomised clinical trial of cholecalciferol 1250μg (50 000 IU) weekly v. ergocalciferol 1250μg (50 000 IU) weekly for 12 weeks in forty-four non-dialysis-dependent patients with stage 3-5 CKD. The primary outcome was change in total 25(OH)D from baseline to week 12 (immediately after therapy). Secondary analyses included the change in 1,25-dihydroxyvitamin D (1,25(OH)2D), parathyroid hormone (PTH), D2 and D3 sub-fractions of 25(OH)D and 1,25(OH)2D and total 25(OH)D from baseline to week 18 (6 weeks after therapy). Cholecalciferol therapy yielded a greater change in total 25(OH)D (45·0 (sd 16·5) ng/ml) v. ergocalciferol (30·7 (sd 15·3) ng/ml) from baseline to week 12 (P<0·01); this observation partially resulted from a substantial reduction in the 25(OH)D3 sub-fraction with ergocalciferol. However, following cessation of therapy, no statistical difference was observed for total 25(OH)D change from baseline to week 18 between cholecalciferol and ergocalciferol groups (22·4 (sd 12·7) v. 17·6 (sd 8·9) ng/ml, respectively; P=0·17). We observed no significant difference between these therapies with regard to changes in serum PTH or 1,25(OH)2D. Therapy with cholecalciferol, compared with ergocalciferol, is more effective at raising serum 25(OH)D in non-dialysis-dependent CKD patients while active therapy is ongoing. However, levels of 25(OH)D declined substantially in both arms following cessation of therapy, suggesting the need for maintenance therapy to sustain levels.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.